Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance

INTRODUCTION: 2018 World Health Organization (WHO) guidelines for the treatment of isoniazid (H)-resistant (Hr) tuberculosis recommend a four-drug regimen: rifampicin (R), ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx), with or without H ([H]RZE-Lfx). This is used once Hr is known, such tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Stagg, Helen R., Bothamley, Graham H., Davidson, Jennifer A., Kunst, Heinke, Lalor, Maeve K., Lipman, Marc C., Loutet, Miranda G., Lozewicz, Stefan, Mohiyuddin, Tehreem, Abbara, Aula, Alexander, Eliza, Booth, Helen, Creer, Dean D., Harris, Ross J., Kon, Onn Min, Loebinger, Michael R., McHugh, Timothy D., Milburn, Heather J., Palchaudhuri, Paramita, Phillips, Patrick P.J., Schmok, Erik, Taylor, Lucy, Abubakar, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785706/
https://www.ncbi.nlm.nih.gov/pubmed/31371444
http://dx.doi.org/10.1183/13993003.00982-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785706/
https://www.ncbi.nlm.nih.gov/pubmed/31371444
http://dx.doi.org/10.1183/13993003.00982-2019

Ejemplares similares